Shingles vaccine linked to 24% lower dementia risk
- The Shingrix shingles vaccine is linked to a 24% lower risk of dementia in adults aged 66 and older over a four-year period based on a study of over 500,000 people in skilled nursing facilities.
- Among vaccinated individuals, 18.8% developed dementia compared to 24.6% of unvaccinated participants, suggesting one dementia case may be prevented for every 17 vaccinated people.
- Researchers analyzed Medicare claims and electronic health records using target trial emulation methods to adjust for health differences.
- Although the observational study cannot prove causation, researchers suggest potential neuroprotective effects of the vaccine and recommend randomized clinical trials for confirmation.
39 Articles
39 Articles
Current shingles vaccine linked to lower risk of coronary heart disease, stroke and heart failure
Shingles is a painful and serious condition affecting many older people. It is caused by the herpes zoster virus, which can flare up in people who previously had chickenpox. A vaccine against shingles (Zostavax) was introduced in 2006. In many countries, including the U.K. and U.S., Zostavax has now been withdrawn and replaced by a much more effective recombinant vaccine (Shingrix). In the U.K., Shingrix is being offered by the NHS to all older …
Those who can be vaccinated with Shingrix could have additional health benefits. Researchers observe a slightly reduced risk of cardiovascular disease
Shingles vaccine found to lower risk of heart diseases, strokes
A Nature Medicine study found lower cardiovascular burden in older adults who received Shingrix instead of the older live shingles vaccine. The findings have sharpened interest in benefits beyond shingles prevention, though trials are still needed to confirm any direct effect.
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
